Trademark: 90302471
Word
TIZUREST
Status
Pending
Status Code
732
Status Date
Monday, July 22, 2024
Serial Number
90302471
Mark Type
4
Filing Date
Friday, November 6, 2020
Published for Opposition
Tuesday, December 13, 2022

Trademark Owner History

Classifications
5 Chemical pharmaceutical preparations in the nature of chemical preparations for pharmaceutical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; human medicines for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; biochemical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; pharmaceutical preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medicinal capsules for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical chemical preparations in the nature of chemical preparations for medical purposes for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical biological preparations for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical ointments, namely, medicated ointments for treating or preventing inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical drugs for the treatment or prevention of inflammatory disease, graft-versus-host disease, liver diseases, lung diseases, pancreatic diseases, intestinal disorders, nerve damage diseases, neurodegenerative diseases, systemic inflammatory response syndrome, sepsis, multiple organ dysfunction syndrome, and metabolic disorders; medical diagnostic preparations

Trademark Events
Nov 10, 2020
New Application Entered
Jan 6, 2021
New Application Office Supplied Data Entered
Apr 14, 2021
Assigned To Examiner
Apr 16, 2021
Priority Action E-Mailed
Apr 16, 2021
Priority Action Written
Apr 16, 2021
Notification Of Priority Action E-Mailed
Jun 16, 2021
Automatic Update Of Assignment Of Ownership
Sep 30, 2021
Teas Response To Office Action Received
Sep 30, 2021
Correspondence Received In Law Office
Oct 1, 2021
Teas/Email Correspondence Entered
Apr 20, 2022
Inquiry To Suspension E-Mailed
Oct 4, 2021
Suspension Letter Written
Oct 4, 2021
Letter Of Suspension E-Mailed
Oct 4, 2021
Notification Of Letter Of Suspension E-Mailed
Apr 20, 2022
Suspension Inquiry Written
Apr 20, 2022
Notification Of Inquiry As To Suspension E-Mailed
Sep 26, 2022
Teas Response To Suspension Inquiry Received
Nov 8, 2022
Assigned To Lie
May 31, 2022
Assigned To Examiner
Nov 10, 2022
Correspondence Received In Law Office
Nov 10, 2022
Teas/Email Correspondence Entered
Nov 10, 2022
Approved For Pub - Principal Register
Nov 23, 2022
Notification Of Notice Of Publication E-Mailed
Dec 13, 2022
Official Gazette Publication Confirmation E-Mailed
Dec 13, 2022
Published For Opposition
Aug 7, 2023
Sou Extension 1 Granted
Feb 7, 2023
Noa E-Mailed - Sou Required From Applicant
Aug 7, 2023
Sou Teas Extension Received
Aug 7, 2023
Sou Extension 1 Filed
Aug 9, 2023
Notice Of Approval Of Extension Request E-Mailed
Jan 22, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Jan 3, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 3, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 3, 2024
Teas Change Of Correspondence Received
Jan 22, 2024
Teas Change Of Correspondence Received
Jan 22, 2024
Teas Change Of Owner Address Received
Feb 5, 2024
Sou Extension 2 Filed
Feb 5, 2024
Sou Extension 2 Granted
Jul 23, 2024
Sou Extension 3 Granted
Jul 23, 2024
Sou Extension 3 Filed
Jul 24, 2024
Notice Of Approval Of Extension Request E-Mailed
Jul 22, 2024
Sou Teas Extension Received
Feb 5, 2024
Sou Teas Extension Received
Feb 7, 2024
Notice Of Approval Of Extension Request E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24